Canada
· Delayed Price · Currency is CAD Medicenna Therapeutics Company Description
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases.
It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors.
The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors.
In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines.
The company is headquartered in Toronto, Canada.
| Country | Canada |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Dr. Fahar Merchant Ph.D. |
Contact Details
Address: 2 Bloor Street West Toronto, ON M4W 3E2 Canada | |
| Phone | 416- 648-5555 |
| Website | medicenna.com |
Stock Details
| Ticker Symbol | MDNA |
| Exchange | TSX |
| Fiscal Year | April - March |
| Reporting Currency | CAD |
| ISIN Number | CA58490H1073 |
Key Executives
| Name | Position |
|---|---|
| Dr. Fahar Merchant Ph.D. | Founder, Chairman, President and Chief Executive Officer |
| Rosemina Merchant B.Sc., M.E.Sc | Founder and Chief Development Officer |
| David Hyman CA, CBV | Chief Financial Officer |
| Dr. Samuel R. Denmeade M.D. | Scientific Advisor |